Información e Inscripción
desde el 18 de abril al 18 de mayo de 2023
Multidisciplinar de
Cáncer de Tiroides
OnLine
de Impacto
OnLine
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head an…
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer - PubMed
The ficlatuzumab-cetuximab arm met significance criteria for PFS and warrants phase III development. HPV-negative HNSCC ...
pubmed.ncbi.nlm.nih.gov
El tabaco es responsable de un 33% de cánceres a nivel mundial, y de hasta un 22% de las muertes por cáncer.
Por una Europa libre de tabaco 👇🏻 https://twitter.com/ECI_TFE/status/1639402154652778497
https://bit.ly/Tobacco_FreeEurope
How does exposure to tobacco smoke evolve in Spain? 🇪🇸
There is a clear positive evolution in indoor exposure to tobacco smoke, from 48% of the population having no daily exposure to smoke in 2009 to 92% in 2020. 💪🏽
#ECTohMadrid #ECToH2023
Cisplatin-Induced Ototoxicity: A Concise Review of the Burden, Prevention, and Interception Strategies https://ascopubs.org/doi/full/10.1200/OP.22.00710?bid=253535602&md5=58ee1db3e7072e14254050ffec723f09&cid=DM13074#.ZBtJUE57lWo.twitter
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head an…
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer - PubMed
The ficlatuzumab-cetuximab arm met significance criteria for PFS and warrants phase III development. HPV-negative HNSCC ...
pubmed.ncbi.nlm.nih.gov
El tabaco es responsable de un 33% de cánceres a nivel mundial, y de hasta un 22% de las muertes por cáncer.
Por una Europa libre de tabaco 👇🏻 https://twitter.com/ECI_TFE/status/1639402154652778497
https://bit.ly/Tobacco_FreeEurope
How does exposure to tobacco smoke evolve in Spain? 🇪🇸
There is a clear positive evolution in indoor exposure to tobacco smoke, from 48% of the population having no daily exposure to smoke in 2009 to 92% in 2020. 💪🏽
#ECTohMadrid #ECToH2023
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head an…
Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer - PubMed
The ficlatuzumab-cetuximab arm met significance criteria for PFS and warrants phase III development. HPV-negative HNSCC ...
pubmed.ncbi.nlm.nih.gov
El tabaco es responsable de un 33% de cánceres a nivel mundial, y de hasta un 22% de las muertes por cáncer.
Por una Europa libre de tabaco 👇🏻 https://twitter.com/ECI_TFE/status/1639402154652778497
https://bit.ly/Tobacco_FreeEurope
How does exposure to tobacco smoke evolve in Spain? 🇪🇸
There is a clear positive evolution in indoor exposure to tobacco smoke, from 48% of the population having no daily exposure to smoke in 2009 to 92% in 2020. 💪🏽
#ECTohMadrid #ECToH2023
TTCC en cifras
Entidades Colaboradoras
